Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology · Invasive Ductal Carcinoma

What Causes Invasive Ductal Carcinoma? Risk Factors

At a Glance

Invasive ductal carcinoma usually has no single identifiable cause. Risk reflects a combination of age, genetics, family history, breast density, prior breast conditions or chest radiation, hormones, and lifestyle factors, and having a risk factor does not mean you caused the cancer.

It is natural to look for a cause or wonder if you did something wrong when diagnosed with cancer. The truth is, there is almost never a single “cause” for invasive ductal carcinoma (IDC, cancer that began in the milk ducts and spread to surrounding tissue) that a person can pinpoint, and you did not cause your cancer. IDC develops from a complex combination of genetic, environmental, and biological factors over many years.

While researchers have identified several “risk factors” that increase the statistical chance of getting breast cancer across large populations, having a risk factor doesn’t mean it directly caused your individual cancer. In fact, many people who get cancer have no known risk factors at all. Most epidemiologic studies report risk factors for breast cancer overall, meaning these associations generally cannot explain why you developed the IDC subtype specifically, nor can routine tests identify the precise cause of your tumor.

Factors Beyond Your Control

Age and Sex
Having female breast tissue and getting older are the most significant risk factors for breast cancer [1][2]. Most breast cancers are diagnosed in older individuals simply because the longer we live, the more time there is for cellular changes to accumulate. (Note: men and some transgender or gender-diverse people can also develop breast cancer [1]).

Family History and Genetics
Having a first-degree relative (like a mother, sister, or daughter) with breast cancer increases your risk, even if a specific gene isn’t identified [3]. Furthermore, inheriting certain pathogenic variants (harmful mutations in your DNA) in genes like BRCA1, BRCA2, PALB2, or CHEK2 raises the risk of developing breast cancer [4][5]. A multigene panel test and genetic counseling can help clarify this inherited risk for you and your family [6]. However, testing is not a crystal ball: a negative result does not eliminate all familial risk, and variants of uncertain significance (VUS) are common and usually not harmful [7].

Breast Density
Women with dense breasts (a mammogram finding meaning they have more fibrous and glandular tissue compared to fatty tissue) have a higher risk of breast cancer [8]. Dense tissue can also make it harder to spot small tumors on a standard mammogram, though having dense breasts is not something you caused.

Prior Breast Conditions
A history of certain breast conditions changes your risk profile. For example, ductal carcinoma in situ (DCIS) is a stage 0, noninvasive breast cancer. While it has not invaded surrounding tissue (and thus is not IDC), having a history of DCIS, or other conditions like lobular carcinoma in situ (LCIS) or atypical hyperplasia, can increase the likelihood of later developing an invasive breast cancer [8][9].

Prior Chest Radiation
If you received therapeutic radiation therapy to the chest (for example, to treat Hodgkin lymphoma during childhood or young adulthood), this is an established risk factor for later developing breast cancer, as developing breast tissue is highly sensitive to radiation [10][11].

Hormones and Medical Exposures

Reproductive History
Long-term exposure to natural hormones like estrogen and progesterone plays a role. Starting your menstrual period early or going through menopause late extends the amount of time your breast tissue is exposed to these hormones, which is associated with a modestly increased risk across populations [12][13]. Having your first child at an older age or never giving birth has been linked to a higher risk for some breast cancer subtypes, whereas breastfeeding has been observationally associated with a lower risk [14][15]. These are observational study trends, not strict rules or explanations for your diagnosis.

Hormonal Medications
Long-term use of combined estrogen and progestin Hormone Replacement Therapy (HRT, medications taken to relieve menopause symptoms) is linked to a higher breast cancer risk [16][17]. Current or recent use of hormonal contraceptives also carries a very small absolute increase in risk [18]. If you are currently taking HRT or hormonal contraceptives, do not abruptly stop them out of panic; instead, discuss safe alternatives with your oncology team based on your specific tumor type (such as hormone-receptor status).

Lifestyle Factors: Releasing the Blame

It is crucial to understand that lifestyle factors explain risk across populations, not blame for an individual. None of these factors act alone, and having a lifestyle risk factor does not mean you are at fault for your diagnosis.

  • Alcohol: Regular alcohol consumption is linked to an increased risk of breast cancer [19][20].
  • Weight: Having a higher body weight, particularly after menopause, is associated with increased risk [21].
  • Physical Activity: Regular exercise has been shown to lower the risk of breast cancer overall [22].

It is easy to look backward and wonder if having a glass of wine, skipping the gym, or delaying childbirth caused your invasive ductal carcinoma. Cancer is not a punishment for your lifestyle choices. Moving forward, healthy habits can support your overall well-being and recovery. Activity and nutrition plans should be individualized during your cancer care, serving as tools for healing rather than reasons for guilt.

Common questions in this guide

What usually causes invasive ductal carcinoma?
Invasive ductal carcinoma usually does not have one identifiable cause. It develops through a complex combination of genetic, biological, environmental, and age-related changes over time, and many people have no known risk factors.
Does having a breast cancer risk factor mean I caused my cancer?
No. A risk factor changes the statistical likelihood of breast cancer across a population but does not prove what caused an individual tumor. Invasive ductal carcinoma is not a punishment for lifestyle choices, and you did not cause your cancer.
Which personal or family factors can increase breast cancer risk?
Risk can be higher with older age, female breast tissue, a close family history of breast cancer, inherited changes in genes such as BRCA1, BRCA2, PALB2, or CHEK2, and dense breasts. Previous DCIS, LCIS, atypical hyperplasia, or therapeutic chest radiation can also increase risk.
Should I consider genetic counseling or inherited testing after an IDC diagnosis?
A genetic counselor can review your personal and family history and determine whether inherited testing may help guide your care or screening for relatives. A negative result does not remove all family-related risk, and a variant of uncertain significance usually does not show that a harmful mutation is present.
Can hormones, alcohol, or body weight affect breast cancer risk?
Longer exposure to natural hormones, long-term combined hormone replacement therapy, and current or recent hormonal contraceptive use are associated with changes in breast cancer risk. Regular alcohol use and higher body weight after menopause are also associated with higher risk, while regular physical activity is associated with lower risk overall.
What is the difference between inherited genetic testing and tumor testing?
Inherited, or germline, testing looks for genetic changes present throughout the body that may affect you and your relatives. Tumor testing examines the cancer cells for features that can help characterize the tumor and guide treatment. Your oncology team or a genetic counselor can explain whether you need one or both.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my stage, grade, and hormone receptor results, and how do they affect my treatment plan?
  2. 2.Would genetic counseling and inherited (germline) testing change my treatment, or affect screening recommendations for my relatives?
  3. 3.How does my personal history, including any prior chest radiation or breast conditions, affect my long-term surveillance (follow-up monitoring) plan?
  4. 4.Are there any lifestyle changes, such as physical activity or nutrition, that you recommend to support my overall health during treatment and recovery?
  5. 5.What is the difference between testing my tumor for its characteristics and testing my inherited genes, and do I need both?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Case Report: A combination of CHEK2 and high polygenic risk score leads to early-onset male breast cancer.

    Tamindarov K, Frank M, Wegscheider S, et al.

    Frontiers in oncology 2026; (16()):1764722 doi:10.3389/fonc.2026.1764722.

    PMID: 41919251
  2. 2

    A rare invasive male breast cancer of nonspecific type presenting at a primary care clinic: Importance of early diagnosis and management.

    Mansoor NS, Arifin F, Kornain NKM, Razalli MM

    Journal of family & community medicine 2023; (30(1)):65-67 doi:10.4103/jfcm.jfcm_210_22.

    PMID: 36843866
  3. 3

    Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study.

    Mukama T, Fallah M, Brenner H, et al.

    BMC medicine 2020; (18(1)):295 doi:10.1186/s12916-020-01772-x.

    PMID: 33148280
  4. 4

    Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.

    , Dorling L, Carvalho S, et al.

    The New England journal of medicine 2021; (384(5)):428-439 doi:10.1056/NEJMoa1913948.

    PMID: 33471991
  5. 5

    Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women.

    Fu F, Zhang D, Hu L, et al.

    Cancer biology & medicine 2021; (19(2)).

    PMID: 34606182
  6. 6

    Multi-gene panel analysis in BRCA1/2-negative patients suspected of hereditary breast and ovarian cancer syndrome: Real-world data from a single institution.

    Nakahara M, Ushiama M, Tanabe N, et al.

    The journal of obstetrics and gynaecology research 2024; (50(9)):1591-1597 doi:10.1111/jog.16026.

    PMID: 39077936
  7. 7

    Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer.

    Willoughby A, Andreassen PR, Toland AE

    Journal of personalized medicine 2019; (9(1)) doi:10.3390/jpm9010015.

    PMID: 30832243
  8. 8

    Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.

    Ko H, Shin J, Lee JE, et al.

    BMC cancer 2017; (17(1)):821 doi:10.1186/s12885-017-3841-0.

    PMID: 29207971
  9. 9

    Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.

    Gorringe KL, Fox SB

    Frontiers in oncology 2017; (7()):248 doi:10.3389/fonc.2017.00248.

    PMID: 29109942
  10. 10

    Incidence of Breast Cancer in the Life Span Study of Atomic Bomb Survivors: 1958-2009.

    Brenner AV, Preston DL, Sakata R, et al.

    Radiation research 2018; (190(4)):433-444 doi:10.1667/RR15015.1.

    PMID: 30044713
  11. 11

    Best practice & research clinical haematology: Screening for breast cancer in hodgkin lymphoma survivors.

    Wong SM

    Best practice & research. Clinical haematology 2023; (36(4)):101525 doi:10.1016/j.beha.2023.101525.

    PMID: 38092481
  12. 12

    Duration of ovarian hormone exposure and gynecological cancer risk in Korean women: the Korean Heart Study.

    Jung KJ, Park C, Yun YD, Jee SH

    Cancer epidemiology 2016; (41()):1-7.

    PMID: 26773407
  13. 13

    Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies.

    Jung AY, Ahearn TU, Behrens S, et al.

    Journal of the National Cancer Institute 2022; (114(12)):1706-1719 doi:10.1093/jnci/djac117.

    PMID: 35723569
  14. 14

    Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.

    Lambertini M, Santoro L, Del Mastro L, et al.

    Cancer treatment reviews 2016; (49()):65-76.

    PMID: 27529149
  15. 15

    Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis.

    Ma H, Ursin G, Xu X, et al.

    Breast cancer research : BCR 2017; (19(1)):6 doi:10.1186/s13058-016-0799-9.

    PMID: 28086982
  16. 16

    Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.

    DeBono NL, Robinson WR, Lund JL, et al.

    Journal of women's health (2002) 2018; (27(3)):377-386 doi:10.1089/jwh.2016.6063.

    PMID: 28570827
  17. 17

    Evaluation of breast risk at menopause: what impact on the use of menopausal hormone therapy?

    Rodrigues MAH, Gompel A

    Maturitas 2026; (211()):108998 doi:10.1016/j.maturitas.2026.108998.

    PMID: 42202686
  18. 18

    Contemporary Hormonal Contraception and the Risk of Breast Cancer.

    Mørch LS, Skovlund CW, Hannaford PC, et al.

    The New England journal of medicine 2017; (377(23)):2228-2239 doi:10.1056/NEJMoa1700732.

    PMID: 29211679
  19. 19

    Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies.

    Jung S, Wang M, Anderson K, et al.

    International journal of epidemiology 2016; (45(3)):916-28 doi:10.1093/ije/dyv156.

    PMID: 26320033
  20. 20

    Alcohol consumption, blood DNA methylation and breast cancer: a Mendelian randomisation study.

    Zhou X, Yu L, Wang L, et al.

    European journal of epidemiology 2022; (37(7)):701-712 doi:10.1007/s10654-022-00886-1.

    PMID: 35708873
  21. 21

    Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.

    Kerr J, Anderson C, Lippman SM

    The Lancet. Oncology 2017; (18(8)):e457-e471 doi:10.1016/S1470-2045(17)30411-4.

    PMID: 28759385
  22. 22

    Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies.

    Pizot C, Boniol M, Mullie P, et al.

    European journal of cancer (Oxford, England : 1990) 2016; (52()):138-54.

    PMID: 26687833

This page is for informational purposes only and does not constitute medical advice. It explains population-level risk factors but cannot identify the cause of an individual tumor; discuss your personal risk and care plan with your oncology team.

Get notified when new evidence is published on breast ductal adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.